» Articles » PMID: 12352596

FDG-PET Improves the Management of Patients with Suspected Recurrence of Colorectal Cancer

Overview
Journal Nucl Med Commun
Specialty Nuclear Medicine
Date 2002 Sep 28
PMID 12352596
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to assess the influence of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) detection of recurrent disease on the management of patients with colorectal cancer and suspected recurrence. One hundred and twenty patients with suspected recurrence were studied with FDG-PET. Fifty-eight patients were referred for FDG-PET because of the elevation of serum tumour markers. Thirty-one patients were referred because of inconclusive results of conventional imaging modalities. Twenty-five patients had known recurrence and were referred for pre-surgical assessment. Six patients were referred because of abdominal pain. A major management change was considered when, as a consequence of FDG-PET results, medical treatment was changed to surgical, or surgical to medical or to no treatment. A minor management change was considered when changes were made within a treatment modality. Of the 58 patients with elevated serum carcinoembryonic antigen (CEA), FDG-PET detected recurrence and led to a major management change in 34 (58%). Eighteen underwent curative surgery and 16 were treated with systemic therapy. Of the 31 patients evaluated because of inconclusive results of conventional imaging modalities, FDG-PET was positive for recurrence in 24 and negative in seven. A major management change took place in 14 patients (45%). Of the 25 patients evaluated to rule out other sites of disease before surgery, FDG-PET did not show any other site of recurrence in 13 (52%) and showed more lesions in the remaining patients. Major management change took place in eight patients (32%). Overall, in the 120 patients studied, FDG-PET resulted in major management changes in 58 (48%), minor changes in four (3%) and no change in 54 (45%). It can be concluded that FDG-PET has a significant impact on the management of patients with suspected recurrence of colorectal cancer. FDG-PET detection of recurrence frequently allows curative surgical intervention. The early identification of distant metastases may also facilitate the implementation of systemic treatment.

Citing Articles

PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on F-FDG.

Zirakchian Zadeh M Clin Exp Metastasis. 2023; 40(6):465-491.

PMID: 37682423 DOI: 10.1007/s10585-023-10231-9.


Blood CEA levels for detecting recurrent colorectal cancer.

Nicholson B, Shinkins B, Pathiraja I, Roberts N, James T, Mallett S Cochrane Database Syst Rev. 2015; (12):CD011134.

PMID: 26661580 PMC: 7092609. DOI: 10.1002/14651858.CD011134.pub2.


Utility of Tc-PEG4-E[PEG4-c(RGDfK)]2 in Posttherapy Surveillance of Patients with Reelevated Carcinoembryonic Antigen Levels.

Gao R, Zhang G, Chen L, Zhu Z, Wang F, Yang A Med Princ Pract. 2015; 24(3):244-9.

PMID: 25871432 PMC: 5639622. DOI: 10.1159/000381287.


Association between carcinoembryonic antigen levels and the applied value of F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative recurrent and metastatic colorectal cancer.

Bu W, Wei R, Li J, Wang L, Shi C, Song J Oncol Lett. 2014; 8(6):2649-2653.

PMID: 25364443 PMC: 4214442. DOI: 10.3892/ol.2014.2523.


F-18 FDG PET/CT in the assessment of patients with unexplained CEA rise after surgical curative resection for colorectal cancer.

Giacomobono S, Gallicchio R, Capacchione D, Nardelli A, Gattozzi D, Lettini G Int J Colorectal Dis. 2013; 28(12):1699-705.

PMID: 23846517 DOI: 10.1007/s00384-013-1747-0.